CN114133367B - 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 - Google Patents

一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 Download PDF

Info

Publication number
CN114133367B
CN114133367B CN202111209332.7A CN202111209332A CN114133367B CN 114133367 B CN114133367 B CN 114133367B CN 202111209332 A CN202111209332 A CN 202111209332A CN 114133367 B CN114133367 B CN 114133367B
Authority
CN
China
Prior art keywords
mmol
cdcl
nmr
dihydropyrone
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111209332.7A
Other languages
English (en)
Other versions
CN114133367A (zh
Inventor
郑楠
宋汪泽
郑玉斌
刘玥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changshu Research Institute Of Dlut Co ltd
Original Assignee
Changshu Research Institute Of Dlut Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changshu Research Institute Of Dlut Co ltd filed Critical Changshu Research Institute Of Dlut Co ltd
Priority to CN202111209332.7A priority Critical patent/CN114133367B/zh
Publication of CN114133367A publication Critical patent/CN114133367A/zh
Application granted granted Critical
Publication of CN114133367B publication Critical patent/CN114133367B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255—Phosphorus containing compounds
    • B01J31/0257—Phosphorus acids or phosphorus acid esters
    • B01J31/0258—Phosphoric acid mono-, di- or triesters ((RO)(R'O)2P=O), i.e. R= C, R'= C, H
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明应用于有机合成技术领域，是一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法。在有机溶剂中，在(PhO)2P(O)OH催化作用下，亚砜亚胺化合物与二氢吡喃酮化合物的发生亲核取代反应制备亚砜亚胺基二氢吡喃酮类衍生物。该方法条件温和、操作简单、官能团兼容性好，避免了传统方法中使用的贵金属催化剂。

Description

一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法
技术领域
本发明应用于有机合成技术领域，是一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法。
背景技术
亚砜亚胺类化合物是砜基的一种含氮类似物，由于其独特的结构与性质，自从被发现以来一直备受关注，并展示出广泛的生物活性(Eur.J.Med.Chem.2017,126,225–245)。此外，亚砜亚胺也被用作试剂(Acc.Chem.Res.1973,6,341–347)、手性助剂(J.Am.Chem.Soc.1995,117,2453–2466)、手性配体(J.Am.Chem.Soc.2001,123,3830–3831)、有机催化剂(J.Org.Chem.2012,8,1443–1451)等。通过亚砜亚胺能够实现各种转化反应,包括芳基化、烷基化、乙烯基化、炔基化和其他反应(Asian J.Org.Chem.2020,9,2035-2082及Chem.Rec.2021,21,396-416)。但是，目前还没有合成亚砜亚胺基二氢吡喃酮的方法被报道出来。
含有N-糖苷键结构的氮苷糖具有广泛的药理作用，是一些抗生素、抗肿瘤药物和抗病毒药物等的重要母环结构(Chem.Rev.1996,96,683及Synlett.2009,07,1154-1156及Synthesis.2009,4143)。使用Achmatowicz重排反应的产物二氢吡喃酮为糖基供体的“denovo”从头合成糖的策略已成为合成糖苷化合物的重要方法之一(Chem.Asian J.2017,12,1027-1042)。2006年，O’Doherty等人以6-氯嘌呤和Boc保护的二氢吡喃酮为原料，通过形成π-烯丙基钯中间体，实现了高对映选择性及非对映选择性合成氮苷糖类衍生物(Org.Lett.2006,8,293–296)。2020年，申请人以Boc保护的二氢吡喃酮为供体，甲基香豆素为受体，通过钯催化烯丙基-烯丙基偶联反应，在温和条件下实现了高对映选择性及非对映选择性合成碳苷糖类衍生物(Adv.Synth.Catal.2021,363,846-850)。除了钯催化剂以外，铱也能够催化类似的反应。2018年，申请人在温和的条件下，以羟基无保护的二氢吡喃酮为供体，通过形成π-烯丙基铱中间体实现高区域选择性和非对映选择性合成氮杂糖类衍生物(J.Org.Chem.2018,83,12822-12830)。但是，上述方法多是使用了昂贵的金属催化剂来用于催化。因此，发展一种无金属催化的de novo合成糖苷类化合物的新策略是非常重要的，尤其是对金属残留指标要求较高的制药行业中。
发明内容
本发明的目的是克服现有技术中的不足，本发明提出了一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法，该方法条件温和、操作简单、官能团兼容性好，避免了传统方法中使用的贵金属催化剂，包括以亚砜亚胺和二氢吡喃酮为原料的制备亚砜亚胺基二氢吡喃酮类衍生物的方法。
本发明是通过如下技术方案实现上述目的的，一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法，
在有机溶剂中，在(PhO)2P(O)OH催化作用下，式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的发生亲核取代反应制备式III所示亚砜亚胺基二氢吡喃酮类衍生物，反应式如下：
Figure BDA0003308271050000031
其中，R1和R2独立地为烷基或芳基，R3为氢、烷基或芳基；I为亚砜亚胺类化合物，Ⅱ为二氢吡喃酮类化合物；
优选地，R1、R2和R3中烷基为C1-C6的烷基、C3-C8的环烷基。
优选地，所述R1、R2和R3中芳基为苯基或任选位置被Ra取代的苯基；所述Ra为C1-C6的烷基、C1-C6的烷氧基、卤素；
优选地，反应温度为0-60℃，优选为20-30℃，反应时间为12-72h，制备得到收率不低于44％的亚砜亚胺基二氢吡喃酮类衍生物。
优选地，所述式III所示亚砜亚胺基二氢吡喃酮类衍生物为
Figure BDA0003308271050000032
中任意一种。
优选地，式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的摩尔比为1:1-10:1,优选为2:1。
优选地，所述的(PhO)2P(O)OH的用量为二氢吡喃酮的20mol％。
优选地，所述的有机溶剂为乙腈、甲苯、氯仿、二氯甲烷、1,2-二氯乙烷、四氢呋喃、丙酮中的一种或两种以上混合，优选溶剂为氯仿，或二氯甲烷。
本发明的有益效果：
1)本发明中亚砜亚胺和二氢吡喃酮类化合物的布朗斯特酸催化偶联制备方法反应条件温和，产物收率不低于44％
2)本发明方法的原料简单易得，底物范围广，条件温和，反应易操作，产率中等到良好。
3)本发明方法避免了传统上使用的贵金属钯、铱等催化剂，进一步丰富了“denovo”从头合成糖苷类化合物的策略，可为设计与合成氮苷糖类化合物提供方法学基础和指导，制备得到的亚砜亚胺基二氢吡喃酮类衍生物具有潜在的生理活性。
具体实施方式
实施例1：
6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物43mg，产率68％。
Figure BDA0003308271050000041
1H NMR(400MHz,CDCl3)δ8.00(dd,J＝9.7,7.8Hz,4H),7.58–7.48(m,6H),7.00(dd,J＝10.2,3.3Hz,1H),6.09(d,J＝10.3Hz,1H),5.46(d,J＝2.8Hz,1H),4.69(d,J＝16.6Hz,1H),4.05(d,J＝16.6Hz,1H).13C NMR(101MHz,CDCl3)δ195.40,150.50,140.34,139.97,133.06,133.03,129.38,129.33,128.62,128.18,125.80,78.35,67.52.高分辨质谱(ESI,m/z):[M+H]+计算值:C17H16NSO3,314.0845；测量值：314.0849.
实施例2：
2-甲基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于二氯乙烷(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-甲基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物42mg，产率64％，dr＝2:1。
Figure BDA0003308271050000051
主要异构体:1H NMR(600MHz,CDCl3)δ8.00–7.97(m,4H),7.52–7.47(m,6H),6.93(dd,J＝10.1,3.7Hz,1H),6.01(d,J＝10.1Hz,1H),5.51(d,J＝3.1Hz,1H),4.83(q,J＝6.7Hz,1H),1.24(d,J＝6.8Hz,3H).
次要异构体:1H NMR(600MHz,CDCl3)δ8.07–8.02(m,4H),7.57–7.52(m,6H),7.04(dd,J＝10.1,1.2Hz,1H),6.08(dd,J＝10.1,1.7Hz,1H),5.54(d,J＝1.3Hz,1H),4.04–3.99(m,1H),1.31(d,J＝6.6Hz,3H).
13C NMR(151MHz,CDCl3)δ197.89,196.85,152.65,149.17,140.86,140.09,132.96,132.91,132.89,129.31,129.26,129.21,129.07,128.89,128.49,128.10,126.94,125.04,124.79,80.65,77.58,75.92,70.65,15.65,15.14.高分辨质谱(ESI,m/z):[M+H]+计算值：328.1001；测量值：测量值：328.0999.13C NMR和高分辨质谱是针对两种异构体混合物的表征结果，其余实施例相同(针对存在dr值的实施例)。实施例3：
2-乙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于二氯甲烷(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-乙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物48mg，产率70％，dr＝2:1。
Figure BDA0003308271050000061
主要异构体:1H NMR(600MHz,CDCl3)δ8.08–7.96(m,4H),7.56–7.45(m,6H),6.94(dd,J＝10.1,3.6Hz,1H),6.01(d,J＝10.1Hz,1H),5.51(d,J＝2.9Hz,1H),4.64(dd,J＝8.0,3.9Hz,1H),1.92–1.59(m,2H),0.90(t,J＝7.4Hz,3H).
次要异构体:1H NMR(600MHz,CDCl3)δ8.08–7.96(m,4H),7.56–7.45(m,6H),7.05(dd,J＝10.1,1.2Hz,1H),6.08(dd,J＝10.1,1.8Hz,1H),5.56(d,J＝1.3Hz,1H),3.78–3.76(m,1H),1.92–1.59(m,2H),0.78(t,J＝7.4Hz,3H).
13C NMR(151MHz,CDCl3)δ197.58,196.46,152.75,149.36,140.65,140.10,132.93,132.85,129.31,129.27,129.18,129.07,128.93,128.69,128.11,127.96,127.38,125.43,80.83,80.70,77.30,75.73,22.98,22.89,9.62.高分辨质谱(ESI,m/z):[M+H]+理论值：342.1158；测量值：342.1162.
实施例4：
2-丙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-丙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物45mg，产率63％，dr＝1.5:1。
Figure BDA0003308271050000071
主要异构体:1H NMR(400MHz,CDCl3)δ8.07–7.96(m,4H),7.57–7.43(m,6H),6.93(dd,J＝10.1,3.6Hz,1H),6.01(d,J＝10.1Hz,1H),5.49(d,J＝3.6Hz,1H),4.70(dd,J＝8.7,3.7Hz,1H),1.89–1.52(m,2H),1.43–1.12(m,2H),0.91(t,J＝7.4Hz,3H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.07–7.96(m,4H),7.57–7.43(m,6H),7.05(d,J＝10.2Hz,1H),6.08(dd,J＝10.1,1.8Hz,1H),5.55(s,1H),3.83(dd,J＝9.1,2.0Hz,1H),1.89–1.52(m,2H),1.43–1.12(m,2H),0.78(t,J＝7.4Hz,3H).
13C NMR(151MHz,CDCl3)δ197.71,196.67,152.71,149.33,141.07,140.55,140.05,132.93,132.85,132.78,129.32,129.27,129.17,129.05,128.92,128.72,128.14,127.97,127.36,125.37,124.79,80.66,79.26,77.30,74.56,31.62,31.59,18.46,18.19,13.93,13.67.高分辨质谱(ESI,m/z):[M+H]+理论值：356.1314；测量值：测量值：356.1319.实施例5：
2-异丙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于THF(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-异丙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物48mg，产率68％，dr＝2:1。
Figure BDA0003308271050000081
主要异构体:1H NMR(600MHz,CDCl3)δ8.07–7.95(m,4H),7.55–7.45(m,6H),6.94(dd,J＝10.1,3.7Hz,1H),6.01(d,J＝10.0Hz,1H),5.52(d,J＝3.1Hz,1H),4.56(d,J＝3.4Hz,1H),2.35(dddd,J＝16.5,9.6,8.5,4.8Hz,1H),1.00–0.63(m,6H).
次要异构体:1H NMR(600MHz,CDCl3)δ8.07–7.95(m,4H),7.55–7.45(m,6H),7.11–7.05(m,1H),6.08(dd,J＝10.1,1.6Hz,1H),5.61(d,J＝1.0Hz,1H),3.68(s,1H),2.35(dddd,J＝16.5,9.6,8.5,4.8Hz,1H),1.00–0.63(m,6H).
13C NMR(151MHz,CDCl3)δ197.69,196.55,152.87,149.29,141.86,141.06,140.62,140.20,132.93,132.90,132.75,132.68,129.29,129.27,129.14,129.03,128.87,128.81,128.10,127.80,125.83,83.83,80.93,78.89,77.19,28.51,28.09,19.09,16.54,16.08.高分辨质谱(ESI,m/z):[M+H]+理论值：356.1314；测量值：测量值：356.1317.
实施例6：
2-环丙基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-环丙基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物47mg，产率66％，dr＝2:1。
Figure BDA0003308271050000091
主要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.91(m,4H),7.58–7.42(m,6H),6.93(dd,J＝10.1,3.5Hz,1H),6.02(dd,J＝10.1,1.0Hz,1H),5.53–5.50(m,1H),4.14(d,J＝7.6Hz,1H),1.33–1.07(m,1H),0.64–0.10(m,4H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.91(m,4H),7.58–7.42(m,6H),7.02(dd,J＝10.1,1.5Hz,1H),6.09(dd,J＝10.1,2.0Hz,1H),5.53–5.50(m,1H),4.14(d,J＝7.6Hz,1H),1.33–1.07(m,1H),0.64–0.10(m,4H).
13C NMR(151MHz,CDCl3)δ195.82,195.04,151.32,148.25,139.95,139.50,139.43,138.69,131.91,131.84,131.78,128.26,128.19,128.09,128.01,127.86,127.57,127.06,126.84,126.81,126.21,124.46,80.71,79.46,76.73,76.69,10.07,9.82,1.99,1.46,0.03,-0.01.高分辨质谱(ESI,m/z):[M+H]+理论值：354.1158；测量值：测量值：354.1161.实施例7：
2-环戊基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-环戊基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物45mg，产率59％，dr＝1.5:1。
Figure BDA0003308271050000101
主要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.95(m,4H),7.56–7.46(m,6H),6.92(dd,J＝10.1,3.5Hz,1H),6.00(dd,J＝10.1,1.0Hz,1H),5.51(dd,J＝3.5,0.9Hz,1H),4.61(d,J＝5.5Hz,1H),2.54–2.38(m,1H),1.74–1.17(m,8H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.95(m,4H),7.56–7.46(m,6H),7.05(dd,J＝10.1,1.3Hz,1H),6.07(dd,J＝10.1,2.0Hz,1H),5.61(dd,J＝3.3,1.6Hz,1H),3.81(dd,J＝4.7,1.5Hz,1H),2.54–2.38(m,1H),1.74–1.17(m,8H).
13C NMR(151MHz,CDCl3)δ197.72,196.70,152.55,149.20,141.64,140.91,140.52,140.06,132.94,132.90,132.76,132.65,129.30,129.27,129.14,129.04,128.86,128.81,128.14,127.81,125.78,124.79,81.84,80.96,77.48,77.39,39.32,39.27,28.71,28.55,27.23,26.68,25.83,25.67,25.53,25.50.高分辨质谱(ESI,m/z):[M+H]+理论值：382.1471；测量值：382.1473.
实施例8：
2-苯基-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-苯基-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物56mg，产率72％，dr＝3:1。
Figure BDA0003308271050000111
主要异构体:1H NMR(400MHz,CDCl3)δ8.05–7.95(m,4H),7.56–7.40(m,6H),7.29–7.22(m,5H),7.03(dd,J＝10.2,3.4Hz,1H),6.15(dd,J＝10.2,1.1Hz,1H),5.71(s,1H),5.59(dd,J＝3.3,1.0Hz,1H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.05–7.95(m,4H),7.56–7.40(m,6H),7.29–7.22(m,5H),7.19(dd,J＝10.2,1.4Hz,1H),6.21(dd,J＝10.2,1.9Hz,1H),5.80(dd,J＝3.3,1.6Hz,1H),4.94(d,J＝1.2Hz,1H).
13C NMR(151MHz,CDCl3)δ195.28,194.28,152.70,150.06,141.19,140.92,140.37,140.00,135.69,135.57,133.03,132.95,132.85,132.78,129.34,129.27,129.20,129.11,128.72,128.19,128.14,128.09,127.99,127.93,127.91,127.84,127.66,127.58,125.77,124.81,81.50,81.49,77.72,77.52.高分辨质谱(ESI,m/z):[M+H]+calcd forC23H20NO3S,390.1158；测量值：390.1158.
实施例9：
2-(对甲苯基)-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-(对甲苯基)-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物63mg，产率78％，dr＝3:1。
Figure BDA0003308271050000121
主要异构体:1H NMR(400MHz,CDCl3)δ8.06–7.99(m,4H),7.56–7.42(m,6H),7.16–7.07(m,4H),7.03(dd,J＝10.2,3.4Hz,1H),6.15(dd,J＝10.1,1.1Hz,1H),5.69(s,1H),5.58(dd,J＝3.3,1.1Hz,1H),2.33(d,J＝3.6Hz,3H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.05–7.98(m,4H),7.56–7.42(m,6H),7.21–7.18(m,1H),7.16–7.07(m,4H),6.21(dd,J＝10.2,1.9Hz,1H),5.79(dd,J＝3.3,1.6Hz,1H),4.93(d,J＝1.1Hz,1H),2.33(d,J＝3.6Hz,3H).
13C NMR(151MHz,CDCl3)δ195.54,194.56,152.67,150.09,141.10,140.94,140.36,140.06,137.82,137.62,133.00,132.95,132.84,132.79,132.61,129.33,129.28,129.18,129.13,128.95,128.79,128.66,128.14,128.01,127.93,127.79,127.61,127.58,125.79,81.51,81.48,77.65,77.53,21.24,21.21.高分辨质谱(ESI,m/z):[M+H]+理论值：C24H22NO3S,404.1314；测量值：404.1311.
实施例10：
2-(4-氯苯基)-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-(4-氯苯基)-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物63mg，产率75％，dr＝3:1。
Figure BDA0003308271050000131
主要异构体:1H NMR(400MHz,CDCl3)δ8.04–7.95(m,4H),7.55–7.40(m,6H),7.29–7.17(m,4H),7.09–7.00(m,1H),6.13(dd,J＝10.2,1.0Hz,1H),5.69(s,1H),5.60(dd,J＝3.5,1.0Hz,1H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.04–7.95(m,4H),7.55–7.40(m,6H),7.29–7.17(m,4H),7.09–7.00(m,1H),6.20(dd,J＝10.2,1.9Hz,1H),5.82(dd,J＝3.3,1.7Hz,1H),4.92(d,J＝1.0Hz,1H).
13C NMR(151MHz,CDCl3)δ194.80,193.72,152.80,149.93,141.39,140.86,140.42,139.79,134.15,134.09,133.90,133.74,133.09,133.00,132.91,132.80,129.39,129.29,129.21,129.14,128.88,128.64,128.59,128.29,128.13,128.03,127.93,127.39,125.59,124.81,81.56,80.56,77.92,76.41.高分辨质谱(ESI,m/z):[M+H]+理论值：C23H19ClNO3S,424.0768；测量值：424.0755.
实施例11：
2-((叔丁基二甲基硅基)氧基)甲基)-6-(oxo-(二苯基-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苯基亚砜亚胺(0.4mmol)和2-((叔丁基二甲基硅基)氧基)甲基)-6-羟基-2H-吡喃-3(6H)-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物46mg，产率50％，dr＝6:1。
Figure BDA0003308271050000141
主要异构体:1H NMR(400MHz,CDCl3)δ8.07–8.00(m,4H),7.56–7.47(m,6H),6.96(dd,J＝10.2,3.4Hz,1H),6.05(dd,J＝10.2,0.9Hz,1H),5.65(dd,J＝3.4,1.0Hz,1H),4.72(dd,J＝4.6,2.6Hz,1H),4.03–3.91(m,2H),0.87–0.82(m,9H),0.05–0.03(m,6H).
次要异构体:1H NMR(400MHz,CDCl3)δ8.07–8.00(m,4H),7.56–7.47(m,6H),7.03(dd,J＝10.2,1.7Hz,1H),6.11(dd,J＝16.6,6.1Hz,1H),5.79(d,J＝2.9Hz,1H),4.38(t,J＝2.2Hz,1H),4.03–3.91(m,2H),0.87–0.82(m,9H),0.05–0.03(m,6H).
13C NMR(101MHz,CDCl3)δ195.63,150.17,140.28,140.15,132.96,132.92,132.59,129.29,129.26,129.15,128.94,128.22,127.92,125.98,77.89,63.38,25.98,25.86,25.64,18.29,-5.42.高分辨质谱(ESI,m/z):[M+H]+理论值：C24H32NO4SSi,458.1816；测量值：458.1815.
实施例12：
6-((二甲基(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二甲基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物29mg，产率77％。
Figure BDA0003308271050000151
1H NMR(400MHz,CDCl3)δ6.94(dd,J＝10.3,2.9Hz,1H),6.08(dd,J＝10.3,1.5Hz,1H),5.64(dd,J＝2.8,1.4Hz,1H),4.45(d,J＝16.4Hz,1H),4.08(d,J＝16.4Hz,1H),3.15(d,J＝0.7Hz,3H),3.08(d,J＝0.6Hz,3H).
13C NMR(101MHz,CDCl3)δ194.90,150.80,126.37,78.04,67.58,44.61,43.69.高分辨质谱(ESI,m/z):[M+H]+理论值：C7H12NO3S,190.0532；测量值：190.0535.
实施例13：
6-((二丁基(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二丁基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物32mg，产率58％。
Figure BDA0003308271050000161
1H NMR(400MHz,CDCl3)δ6.94(dd,J＝10.3,2.9Hz,1H),6.08(dd,J＝10.3,1.4Hz,1H),5.61(dd,J＝2.6,1.3Hz,1H),4.47(d,J＝16.4Hz,1H),4.07(d,J＝16.4Hz,1H),3.25–2.96(m,4H),1.88–1.73(m,4H),1.52–1.41(m,4H),0.97(dd,J＝7.4,6.7Hz,6H).13C NMR(101MHz,CDCl3)δ195.20,151.41,126.16,77.74,67.72,54.86,52.11,25.55,23.62,21.85,21.67,13.60,13.57.高分辨质谱(ESI,m/z):[M+Na]+理论值：C13H23NO3SNa,296.1291；测量值：296.1295.
实施例14：
6-((二苄基(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加二苄基亚砜亚胺(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物35mg，产率52％。
Figure BDA0003308271050000162
1H NMR(400MHz,CDCl3)δ7.47–7.32(m,10H),6.74(dd,J＝10.3,2.8Hz,1H),6.03(dd,J＝10.3,0.9Hz,1H),5.44(s,1H),4.47(d,J＝13.9Hz,1H),4.39(dd,J＝18.7,15.2Hz,2H),4.15(s,2H),4.02(d,J＝16.5Hz,1H).13C NMR(151MHz,CDCl3)δ195.27,151.36,131.49,131.03,129.18,129.05,128.96,128.65,128.60,126.79,126.04,78.05,67.94,62.11,58.53.高分辨质谱(ESI,m/z):[M+Na]+理论值：C19H19NO3SNa,364.0978；测量值：364.0980.
实施例15：
6-((甲基(oxo)(苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加甲基(亚氨基)(苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物33mg，产率66％，dr＝1:1。
Figure BDA0003308271050000171
异构体一:1H NMR(400MHz,CDCl3)δ8.00–7.96(m,2H),7.69–7.56(m,3H),6.93(ddd,J＝11.6,10.4,3.1Hz,1H),6.10–6.05(m,1H),5.45–5.40(m,1H),4.64(d,J＝16.6Hz,1H),3.91(d,J＝16.5Hz,1H),3.20(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.00–7.96(m,2H),7.69–7.56(m,3H),6.93(ddd,J＝11.6,10.4,3.1Hz,1H),6.10–6.05(m,1H),5.45–5.40(m,1H),4.46(d,J＝16.5Hz,1H),4.13–4.07(m,1H),3.15(s,3H).
13C NMR(101MHz,CDCl3)δ195.22,195.15,150.87,150.12,140.11,138.82,133.61,133.46,129.65,129.46,128.24,127.97,126.24,125.80,78.53,77.83,67.59,67.50,45.95,45.62.高分辨质谱(ESI,m/z):[M+H]+理论值：C12H14NO3S,252.0688；测量值：252.0694.
实施例16：
6-((乙基(oxo)(苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加乙基(亚氨基)(苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到无色液体产物25mg，产率48％，dr＝1:1。
Figure BDA0003308271050000181
异构体一:1H NMR(400MHz,CDCl3)δ7.99–7.91(m,2H),7.70–7.56(m,3H),6.95(ddd,J＝11.9,10.3,3.1Hz,1H),6.07(ddd,J＝10.3,2.2,1.3Hz,1H),5.44(ddd,J＝12.0,3.1,1.1Hz,1H),4.66(d,J＝16.6Hz,1H),3.93(d,J＝16.5Hz,1H),3.42–3.19(m,2H),1.32–1.21(m,3H).
异构体二:1H NMR(400MHz,CDCl3)δ7.99–7.91(m,2H),7.70–7.56(m,3H),6.95(ddd,J＝11.9,10.3,3.1Hz,1H),6.07(ddd,J＝10.3,2.2,1.3Hz,1H),5.44(ddd,J＝12.0,3.1,1.1Hz,1H),4.48(d,J＝16.5Hz,1H),4.09(d,J＝16.6Hz,1H),3.42–3.19(m,2H),1.32–1.21(m,3H).
13C NMR(151MHz,CDCl3)δ195.41,195.29,151.21,150.34,138.13,136.67,133.55,133.42,129.55,129.35,129.03,128.82,126.09,125.67,78.49,77.84,67.62,67.52,51.79,51.44,7.58,7.01.高分辨质谱(ESI,m/z):[M+Na]+理论值：C13H15NO3SNa,288.0665；测量值：288.0670.
实施例17：
6-((4-(叔丁基)苯基)(oxo)(苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加(4-(叔丁基)苯基)(亚氨基)(苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物38mg，产率51％，dr＝1:1。
Figure BDA0003308271050000191
异构体一:1HNMR(400MHz,CDCl3)δ8.05–7.89(m,4H),7.56–7.49(m,5H),7.02(t,J＝3.2Hz,1H),6.10(s,1H),5.46(td,J＝3.3,1.1Hz,1H),4.74(d,J＝9.0Hz,1H),4.05(d,J＝7.0Hz,1H),1.30(t,J＝2.3Hz,9H).
异构体二:1H NMR(400MHz,CDCl3)δ8.05–7.89(m,4H),7.56–7.49(m,5H),7.00(t,J＝3.2Hz,1H),6.07(s,1H),5.46(td,J＝3.3,1.1Hz,1H),4.70(d,J＝9.1Hz,1H),4.09(d,J＝7.0Hz,1H),1.30(t,J＝2.3Hz,9H).
13C NMR(151MHz,CDCl3)δ195.50,157.00,156.96,150.64,140.59,140.24,136.91,132.91,132.87,129.31,129.26,128.56,128.53,128.14,128.05,126.45,126.42,125.72,125.67,78.39,78.36,67.49,67.47,35.16,31.03.高分辨质谱(ESI,m/z):[M+H]+理论值：C21H24NO4S,370.1471；测量值：370.1469.
实施例18：
6-((甲基(oxo)(对甲苯基)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(甲基)(对甲苯基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物29mg，产率54％，dr＝1:1。
Figure BDA0003308271050000201
异构体一:1H NMR(400MHz,CDCl3)δ7.91–7.83(m,2H),7.40(t,J＝8.1Hz,2H),6.99–6.90(m,1H),6.09(dd,J＝4.7,1.2Hz,1H),5.41(dd,J＝3.1,1.1Hz,1H),4.65(d,J＝16.6Hz,1H),3.93(d,J＝16.5Hz,1H),3.20(s,3H),2.46(t,J＝3.9Hz,3H).
异构体二:1H NMR(400MHz,CDCl3)δ7.91–7.83(m,2H),7.40(t,J＝8.1Hz,2H),6.99–6.90(m,1H),6.06(dd,J＝4.7,1.2Hz,1H),5.41(dd,J＝3.1,1.1Hz,1H),4.49(d,J＝16.5Hz,1H),4.09(d,J＝16.6Hz,1H),3.15(s,3H),2.46(t,J＝3.9Hz,3H).
13C NMR(151MHz,CDCl3)δ195.31,195.23,151.01,150.22,144.67,144.48,136.78,135.54,130.29,130.10,128.31,128.04,126.16,125.69,78.56,77.81,77.30,77.09,76.88,67.55,67.45,45.94,45.68,21.56.高分辨质谱(ESI,m/z):[M+Na]+理论值：C13H15NO3SNa,288.0665；测量值：288.0670.
实施例19：
6-((4-甲氧基苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(4-甲氧苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物25mg，产率45％，dr＝1:1。
Figure BDA0003308271050000211
异构体一:1H NMR(600MHz,CDCl3)δ7.88(dd,J＝11.3,9.0Hz,2H),7.03(dd,J＝10.1,9.1Hz,2H),6.94–6.89(m,1H),6.08–6.03(m,1H),5.38(dd,J＝9.4,1.7Hz,1H),4.62(d,J＝16.6Hz,1H),3.92(d,J＝16.5Hz,1H),3.87(d,J＝2.4Hz,3H),3.17(s,3H).
异构体二:1H NMR(600MHz,CDCl3)δ7.88(dd,J＝11.3,9.0Hz,2H),7.03(dd,J＝10.1,9.1Hz,2H),6.94–6.89(m,1H),6.08–6.03(m,1H),5.38(dd,J＝9.4,1.7Hz,1H),4.47(d,J＝16.5Hz,1H),4.09–4.05(m,1H),3.87(d,J＝2.4Hz,3H),3.12(s,3H).
13C NMR(151MHz,CDCl3)δ195.35,195.25,163.75,163.67,151.15,150.27,130.54,130.20,126.18,125.68,114.88,114.67,78.53,77.84,67.63,67.46,55.77,55.72,46.16,45.94.高分辨质谱(ESI,m/z):[M+H]+理论值：C13H16NO4S,282.0794；测量值：282.0802.
实施例20：
6-((4-氯苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(4-氯苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物30mg，产率53％，dr＝1:1。
Figure BDA0003308271050000221
异构体一:1HNMR(600MHz,CDCl3)δ7.90(dd,J＝8.5,3.0Hz,2H),7.55(dd,J＝13.9,8.6Hz,2H),6.90(ddd,J＝15.5,10.3,3.0Hz,1H),6.08–6.05(m,1H),5.40(dd,J＝10.8,1.5Hz,1H),4.59(d,J＝16.6Hz,1H),3.91(d,J＝16.5Hz,1H),3.19(s,3H).
异构体二:1H NMR(600MHz,CDCl3)δ7.90(dd,J＝8.5,3.0Hz,2H),7.55(dd,J＝13.9,8.6Hz,2H),6.90(ddd,J＝15.5,10.3,3.0Hz,1H),6.08–6.05(m,1H),5.40(dd,J＝10.8,1.5Hz,1H),4.41(d,J＝16.5Hz,1H),4.08(d,J＝16.6Hz,1H),3.13(s,3H).
13C NMR(151MHz,CDCl3)δ195.02,194.91,150.67,149.93,140.41,140.23,138.70,137.42,129.94,129.77,129.74,129.45,126.30,125.94,78.47,77.72,67.65,67.54,46.05,45.64.高分辨质谱(ESI,m/z):[M+Na]+理论值：C12H12ClNO3SNa,308.0118；测量值：308.0121.
实施例21：
6-((4-溴苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(4-溴苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物39mg，产率59％，dr＝1:1。
Figure BDA0003308271050000231
异构体一:1H NMR(400MHz,CDCl3)δ7.84(dd,J＝8.6,2.4Hz,2H),7.73(t,J＝8.7Hz,2H),6.91(td,J＝10.7,3.0Hz,1H),6.09(d,J＝2.4Hz,1H),5.43(d,J＝2.7Hz,1H),4.60(d,J＝16.6Hz,1H),3.92(d,J＝16.5Hz,1H),3.20(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ7.84(dd,J＝8.6,2.4Hz,2H),7.73(t,J＝8.7Hz,2H),6.91(td,J＝10.7,3.0Hz,1H),6.07(d,J＝2.3Hz,1H),5.41(d,J＝2.5Hz,1H),4.42(d,J＝16.5Hz,1H),4.12–4.07(m,1H),3.14(s,3H).
13C NMR(151MHz,CDCl3)δ195.03,194.92,150.68,149.93,139.29,138.01,132.95,132.75,129.86,129.52,128.96,128.80,126.33,125.97,78.49,77.74,67.69,67.57,46.05,45.65.高分辨质谱(ESI,m/z):[M+Na]+理论值：C12H12BrNO3SNa,351.9613；测量值：351.9620.
实施例22：
6-((3-甲氧基苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(3-甲氧基苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物33mg，产率58％，dr＝1:1。
Figure BDA0003308271050000241
异构体一:1HNMR(600MHz,CDCl3)δ7.55–7.45(m,3H),7.20–7.12(m,1H),6.93(dd,J＝10.3,3.0Hz,1H),6.08–6.06(m,1H),5.41(d,J＝1.7Hz,1H),4.62(d,J＝16.6Hz,1H),3.92(d,J＝16.5Hz,1H),3.87(s,3H),3.19(s,3H).
异构体二:1H NMR(600MHz,CDCl3)δ7.55–7.45(m,3H),7.20–7.12(m,1H),6.90(dd,J＝10.3,3.1Hz,1H),6.05(dd,J＝4.6,0.9Hz,1H),5.39(d,J＝1.8Hz,1H),4.46(d,J＝16.5Hz,1H),4.08(d,J＝16.6Hz,1H),3.86(s,3H),3.14(s,3H).
13C NMR(151MHz,CDCl3)δ195.24,195.24,195.14,160.41,160.21,150.88,150.09,141.24,139.90,130.71,130.49,126.22,125.76,120.26,119.85,119.82,112.93,112.87,78.61,77.78,67.59,67.49,55.78,55.72,45.86,45.60.高分辨质谱(ESI,m/z):[M+Na]+理论值：C13H15NO4SNa,304.0614；测量值：304.0619.
实施例23：
6-((3-溴苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(3-溴苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物42mg，产率64％，dr＝1:1。
Figure BDA0003308271050000251
异构体一:1HNMR(400MHz,CDCl3)δ8.11(dt,J＝3.6,1.8Hz,1H),7.90(ddd,J＝7.9,3.3,1.8Hz,1H),7.77(dddd,J＝9.0,8.0,1.8,0.9Hz,1H),7.46(dt,J＝9.7,7.9Hz,1H),6.95–6.88(m,1H),6.09(dd,J＝4.5,1.3Hz,1H),5.42(dt,J＝2.9,1.4Hz,1H),4.59(d,J＝16.6Hz,1H),4.09(d,J＝16.6Hz,1H),3.20(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.11(dt,J＝3.6,1.8Hz,1H),7.90(ddd,J＝7.9,3.3,1.8Hz,1H),7.77(dddd,J＝9.0,8.0,1.8,0.9Hz,1H),7.46(dt,J＝9.7,7.9Hz,1H),6.95–6.88(m,1H),6.06(dd,J＝4.5,1.3Hz,1H),5.42(dt,J＝2.9,1.4Hz,1H),4.42(d,J＝16.5Hz,1H),3.92(d,J＝16.5Hz,1H),3.15(s,3H).
13C NMR(151MHz,CDCl3)δ195.00,194.92,150.51,149.86,142.38,140.96,136.68,136.49,131.21,131.10,130.92,130.90,126.68,126.44,126.33,125.97,123.66,123.40,78.48,77.65,67.56,46.03,45.56.高分辨质谱(ESI,m/z):[M+Na]+理论值：C12H12BrNO3SNa,351.9613；测量值：351.9620.
实施例24：
6-((2-甲氧基苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(2-甲氧基苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物25mg，产率44％，dr＝1:1。
Figure BDA0003308271050000261
异构体一:1HNMR(400MHz,CDCl3)δ8.11–7.99(m,1H),7.68–7.57(m,1H),7.21–7.04(m,2H),6.94(dd,J＝10.2,3.5Hz,1H),6.03(s,1H),5.41(d,J＝3.3Hz,1H),4.67(d,J＝16.6Hz,1H),3.99(s,3H),3.75(d,J＝16.4Hz,1H),3.35(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.11–7.99(m,1H),7.68–7.57(m,1H),7.21–7.04(m,2H),6.83(dd,J＝10.2,3.3Hz,1H),6.01(s,1H),5.19(d,J＝3.0Hz,1H),4.45(d,J＝16.4Hz,1H),4.04(d,J＝16.6Hz,1H),3.98(s,3H),3.34(s,3H).
13C NMR(151MHz,CDCl3)δ195.70,195.58,156.90,156.63,150.62,150.08,135.70,135.30,131.97,130.75,126.03,125.55,121.25,120.96,112.20,112.07,79.04,76.90,67.20,66.70,56.10,56.06,43.69,43.43.高分辨质谱(ESI,m/z):[M+H]+理论值：C13H16NO4S,282.0794；测量值：282.0798.
实施例25：
6-((2-氯苯基)(甲基)(oxo)-λ-亚砜基)氨基)-2H-吡喃-3(6H)-酮的制备
在空气下，将(PhO)2P(O)OH(0.04mmol)溶于CHCl3(2mL)，添加亚氨基(2-氯苯基)(甲基)-λ-磺胺酮(0.4mmol)和6-羟基-2H-吡喃-3-酮(0.2mmol)于混合物中。将混合物在室温下搅拌18h，旋干后柱层析分离得到黄色液体产物34mg，产率60％，dr＝1:1。
Figure BDA0003308271050000271
异构体一:1H NMR(400MHz,CDCl3)δ8.22(dt,J＝16.8,5.0Hz,1H),7.65–7.43(m,3H),6.90(d,J＝3.4Hz,1H),6.04(s,1H),5.42(d,J＝3.4Hz,1H),4.63(d,J＝16.7Hz,1H),3.83(d,J＝16.6Hz,1H),3.38(s,3H).
异构体二:1H NMR(400MHz,CDCl3)δ8.22(dt,J＝16.8,5.0Hz,1H),7.65–7.43(m,3H),6.88(d,J＝3.4Hz,1H),6.01(s,1H),5.12(d,J＝3.2Hz,1H),4.51(d,J＝16.6Hz,1H),4.02(d,J＝16.7Hz,1H),3.38(s,3H).
13C NMR(151MHz,CDCl3)δ195.27,195.19,150.01,149.51,138.14,134.89,134.85,134.43,133.24,132.31,132.15,132.08,131.97,131.73,128.11,127.67,126.18,125.73,79.16,77.00,67.37,67.36,43.44,43.23.高分辨质谱(ESI,m/z):[M+Na]+理论值：C12H12ClNO3SNa,308.0118；测量值：308.0119.
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (9)

1.一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法，其特征在于：
在有机溶剂中，在(PhO)2P(O)OH催化作用下，式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物发生亲核取代反应制备式III所示亚砜亚胺基二氢吡喃酮类衍生物，反应式如下：
Figure DEST_PATH_IMAGE002
其中，R1和R2独立地为烷基或芳基，R3为氢、烷基或芳基；反应温度为0-60℃，有机溶剂为氯仿、二氯甲烷、1,2-二氯乙烷中的一种或两种以上混合。
2.根据权利要求1所述的方法，其特征在于：R1、R2和R3中烷基为C1-C6的烷基、C3-C8的环烷基。
3.根据权利要求1或2所述的方法，其特征在于：所述R1、R2和R3中芳基为苯基或任选位置被Ra取代的苯基；所述Ra为C1-C6的烷基、C1-C6的烷氧基或卤素。
4.根据权利要求3所述的方法，其特征在于：所述式III所示亚砜亚胺基二氢吡喃酮类衍生物为
Figure DEST_PATH_IMAGE004
、
Figure DEST_PATH_IMAGE006
或
Figure DEST_PATH_IMAGE008
中任意一种。
5.根据权利要求3所述的方法，其特征在于：反应温度为20-30℃，反应时间为12-72 h。
6.根据权利要求3所述的方法，其特征在于：式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的摩尔比为1:1-10:1。
7.根据权利要求6所述的方法，其特征在于：式I所示亚砜亚胺化合物与式II所示二氢吡喃酮化合物的摩尔比为2:1。
8.根据权利要求3所述的方法，其特征在于：所述的(PhO)2P(O)OH的用量为式II所示二氢吡喃酮的20 mol%。
9.根据权利要求3所述的方法，其特征在于：所述的有机溶剂为氯仿或二氯甲烷。
CN202111209332.7A 2021-10-18 2021-10-18 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法 Active CN114133367B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111209332.7A CN114133367B (zh) 2021-10-18 2021-10-18 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111209332.7A CN114133367B (zh) 2021-10-18 2021-10-18 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法

Publications (2)

Publication Number Publication Date
CN114133367A CN114133367A (zh) 2022-03-04
CN114133367B true CN114133367B (zh) 2023-03-21

Family

ID=80394215

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111209332.7A Active CN114133367B (zh) 2021-10-18 2021-10-18 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法

Country Status (1)

Country Link
CN (1) CN114133367B (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016013633A1 (ja) * 2014-07-24 2016-01-28 日本曹達株式会社 アリールオキシ化合物および有害生物防除剤
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CN109180565A (zh) * 2018-09-21 2019-01-11 大连理工大学 一种新型6-烷氧基-2h-二氢吡啶-3酮的制备方法
CN109232391A (zh) * 2018-09-21 2019-01-18 大连理工大学 一种新型6-巯基-2h-二氢吡啶-3酮的制备方法
TW201912641A (zh) * 2017-09-08 2019-04-01 印度商Ｐｉ工業公司 新型殺真菌雜環化合物
CN112409345A (zh) * 2020-11-20 2021-02-26 大连理工大学 一种新型二氢吡喃酮基香豆素类化合物的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016013633A1 (ja) * 2014-07-24 2016-01-28 日本曹達株式会社 アリールオキシ化合物および有害生物防除剤
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
TW201912641A (zh) * 2017-09-08 2019-04-01 印度商Ｐｉ工業公司 新型殺真菌雜環化合物
CN109180565A (zh) * 2018-09-21 2019-01-11 大连理工大学 一种新型6-烷氧基-2h-二氢吡啶-3酮的制备方法
CN109232391A (zh) * 2018-09-21 2019-01-18 大连理工大学 一种新型6-巯基-2h-二氢吡啶-3酮的制备方法
CN112409345A (zh) * 2020-11-20 2021-02-26 大连理工大学 一种新型二氢吡喃酮基香豆素类化合物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
De Novo Asymmetric Synthesis of Homoadenosine via a Palladium-Catalyzed N-Glycosylation;Sanjeeva R. Guppi 等;《Org. Lett.》;20051214;第8卷(第2期);第293-296页 *
Organocatalytic C3-functionalization of indolizines: synthesis of biologically important indolizine derivatives;Yi-Zhu Zhang 等;《Org. Biomol. Chem.》;20200710;第18卷;第5688-5696页 *
布朗斯特酸催化合成亚砜亚胺基二氢吡喃酮类衍生物;孙鑫浩 等;《有机化学》;20211028;第42卷;第487-497页 *

Also Published As

Publication number Publication date
CN114133367A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
CS196376B2 (en) Method for the stereoselective production of optical isomers of hexahydrodibenzopyranone derivatives
Pei et al. DABCO-catalyzed regioselective cyclization reactions of β, γ-unsaturated α-ketophosphonates or β, γ-unsaturated α-ketoesters with allenic esters
Mouradzadegun et al. Thermally-induced ring contraction as a novel and straightforward route for the synthesis of 2-furyl acetonitrile derivatives
EP4186915A1 (en) Method for synthesizing c-nucleoside compound
CN111763148A (zh) 一种含三氟甲基的炔基环戊烯衍生物及其制备方法和应用
CN110156796B (zh) 异恶唑拼接3,3’-硫代吡咯啉酮双螺环氧化吲哚化合物及其制备方法及应用
CN114133367B (zh) 一种亚砜亚胺基二氢吡喃酮类衍生物的制备方法
Wu et al. In (iii)-Catalyzed tandem reaction of chromone-derived Morita–Baylis–Hillman alcohols with amines
CN114957262A (zh) 一种c-6位芳基化去氮嘌呤衍生物的制备方法
CN114591344A (zh) 一种手性螺环四氢呋喃-吡唑啉酮化合物的合成方法
CN111646964B (zh) 一种碱催化的合成2h-吡喃-2-酮衍生物新方法
EP2611811B1 (en) New process for preparing cyclolignans
CN108440526B (zh) 一种手性巴比妥螺四氢喹啉类化合物及制备方法
US5481008A (en) Process for the preparation of optically active compounds
Pan et al. Dioxane-involving reaction for the synthesis of 3-aryl-1-(2-(vinyloxy) ethoxy) isoquinolines catalyzed by AgOTf
CN114848648A (zh) C-6位芳基化去氮嘌呤衍生物在制备抗肿瘤药物中的应用
CN113372353A (zh) 一种二氟烷基化的二氢呋喃喹啉酮衍生物及其制备方法
CN110272417B (zh) 2-甲基-1,8-萘啶类化合物及其制备方法与应用
EP3984982A1 (en) Method for producing morphinan derivative
Otero et al. Preliminary studies on the synthesis of rancinamycins from nitrosugars: first total synthesis of (3S, 4S, 5S, 6R)-5-benzyloxy-6-hydroxy-3, 4-(isopropylidendioxy)-cyclohex-1-enecarbaldehyde
Kadiyala et al. Gold (III) promoted formation of dihydroquinazolinones: double X–H activation by gold
CN107445914B (zh) 一种2,2,5-三取代1,3,4噁二唑衍生物及其合成方法
Tanabe et al. Studies on ring-closing metathesis for the formation of the 11-membered ring system of daphnezomine C
BG62770B1 (bg) Пиронови производни като инхибитори на протеаза и антивирусни агенти
CN106543033B (zh) 一种取代氰基乙酸酯的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant